StockMarketWire.com - Cell-based therapeutics developer ReNeuron Group said it had appointed Nicholas Adams to the newly-created role of vice-president for business development and alliance management.

Adams had recently served as chief business officer at Clavis Pharma and Redx Pharma.

ReNeuron said his appointment reflected tcontinued clinical progress at the company and the anticipated level of interest from potential licensing partners.

'As highlighted in recent announcements, business development has become an increasingly important aspect of the company's activities as we pursue discussions with commercial third parties regarding potential collaboration and/or out-licensing deals across our programmes,' chief executive Olav Hellebo said.



Story provided by StockMarketWire.com